Secreted production of assembled Norovirus virus-like particles from Pichia pastoris

Microbial Cell Factories

Volumn 13, Issue 1, 2014, Pages

  Tomé Amat, Jaime ^a   Fleischer, Lauren ^a   Parker, Stephanie A ^a   Bardliving, Cameron L ^a   Batt, Carl A ^a  

^a Department of Molecular Biology and Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; METHANOL; PROTEIN VP1; BLOOD GROUP ANTIGEN;

ARTICLE; BIOREACTOR; CELL INCLUSION; DOWNSTREAM PROCESSING; ESCHERICHIA COLI; EXPRESSION VECTOR; IMMUNE RESPONSE; INSECT CELL; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; NOROVIRUS; PICHIA PASTORIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SECRETION; SALIVA ANALYSIS; SUPERNATANT; TRANSMISSION ELECTRON MICROSCOPY; YEAST; HUMAN; ISOLATION AND PURIFICATION; LIGHT; METABOLISM; PARTICLE SIZE; PICHIA; RADIATION SCATTERING; SALIVA; ULTRASTRUCTURE; VIRION; VIRUS ASSEMBLY;

BLOOD GROUP ANTIGENS; HUMANS; LIGHT; NOROVIRUS; PARTICLE SIZE; PICHIA; SALIVA; SCATTERING, RADIATION; VIRION; VIRUS ASSEMBLY;

EID: 84908127258     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/s12934-014-0134-z     Document Type: Article

References (49)

1. Tan M, Xia M, Huang PW, Wang LY, Zhong WM, McNeal M, Wei C, Jiang X. Norovirus P particle as a platform for antigen presentation. 4th Vaccine and Isv Annual Global Congress 2011, 4:19-26.
2. Hardy ME. Norovirus protein structure and function. FEMS Microbiol Lett 2005, 253:1-8. 10.1016/j.femsle.2005.08.031.
3. Tan M, Huang PW, Meller J, Zhong WM, Farkas T, Jiang X. Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. J Virol 2003, 77:12562-12571. 10.1128/JVI.77.23.12562-12571.2003.
4. Prasad BVV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray crystallographic structure of the Norwalk virus capsid. Science 1999, 286:287-290. 10.1126/science.286.5438.287.
5. Jiang X, Matson DO, Ruizpalacios GM, Hu J, Treanor J, Pickering LK. Expression, self-assembly, and antigenicity of a snow mountain agent-like calicivirus capsid protein. J Clin Microbiol 1995, 33:1452-1455.
6. Vongpunsawad S, Prasad BVV, Estes MK. Norwalk virus minor capsid protein VP2 associates within the VP1 shell domain. J Virol 2013, 87:4818-4825. 10.1128/JVI.03508-12.
7. Jennings GT, Bachmann MF. Coming of age of virus-like particle vaccines. Biol Chem 2008, 389:521-536. 10.1515/BC.2008.064.
8. Chackerian B. Virus-like particles-flexible platforms for vaccine development. Expert Rev Vaccines 2007, 6:381-390. 10.1586/14760584.6.3.381.
9. Deml L, Speth C, Dierich MP, Wolf H, Wagner R. Recombinant HIV-1 Pr55(gag) virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005, 42:259-277. 10.1016/j.molimm.2004.06.028.
10. Grgacic EVL, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006, 40:60-65. 10.1016/j.ymeth.2006.07.018.
11. Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011, 29:8126-8133. 10.1016/j.vaccine.2011.08.026.
12. Fang H, Tan M, Xia M, Wang LH, Jiang X. Norovirus P particle efficiently elicits innate, humoral and cellular immunity. Plos One 2013, 8:e63269. 10.1371/journal.pone.0063269.
13. Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, McKenzie IFC, Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004, 173:3148-3154. 10.4049/jimmunol.173.5.3148.
14. Frey ST JJ, Atmar RL. Dose Escalation Trial of the Safety and Immunogenicity of a Bivalent Norovirus Virus-Like Particle Vaccine Administered by the Intramuscular Route. 49th Annual Meeting of the Infectious Disease Society of America (IDSA); Boston, MA, USA 2011,
15. Richardson C, Bargatze RF, Goodwin R, Mendelman PM. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev Vaccines 2013, 12:155-167. 10.1586/erv.12.145.
16. Treanor JF S, GormLey R. Safety and Immunogenicity of an Intramuscular Norovirus VLP Vaccine. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA 2012,
17. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A 1996, 93:5335-5340. 10.1073/pnas.93.11.5335.
18. Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, Chen Q, Mason HS. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 2008, 26:1846-1854. 10.1016/j.vaccine.2008.01.053.
19. Thorne LG, Goodfellow IG. Norovirus gene expression and replication. J Gen Virol 2014, 95:278-291. 10.1099/vir.0.059634-0.
20. Xia M, Farkas T, Jiang X. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J Med Virol 2007, 79:74-83. 10.1002/jmv.20762.
21. Lua LHL, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg APJ. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 2014, 111:425-440. 10.1002/bit.25159.
22. Zeltins A. Construction and characterization of virus-like particles: a review. Mol Biotechnol 2013, 53:92-107. 10.1007/s12033-012-9598-4.
23. Koho T, Huhti L, Blazevic V, Nurminen K, Butcher SJ, Laurinmaki P, Kalkkinen N, Ronnholm G, Vesikari T, Hytonen VP, Kulomaa MS. Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus. J Virol Methods 2012, 179:1-7. 10.1016/j.jviromet.2011.05.009.
24. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012, 31:58-83. 10.1016/j.vaccine.2012.10.083.
25. Xi JA, Min W, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992, 66:6527-6532.
26. Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN (vol 178, pg 2361, 2007). J Immunol 2007, 178:6653-6653. 10.4049/jimmunol.178.10.6653.
27. Weinacker D, Rabert C, Zepeda AB, Figueroa CA, Pessoa A, Farias JG. Applications of recombinant Pichia pastoris in the healthcare industry. Braz J Microbiol 2013, 44:1043-1048. 10.1590/S1517-83822013000400004.
28. Lunsdorf H, Gurramkonda C, Adnan A, Khanna N, Rinas U. Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the Hepatitis B surface antigen. Microb Cell Factories 2011, 10:10. 10.1186/1475-2859-10-48.
29. Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, Sood R, Galav A, Wahala W, de Silva A, Swaminathan S, Khanna N. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without Pre-membrane protein and induces high titer neutralizing antibodies. Plos One 2013, 8:e64595. 10.1371/journal.pone.0064595.
30. Tan M, Fang PG, Chachiyo T, Xia M, Huang PW, Fang ZY, Jiang W, Jiang X. Noroviral P particle: structure, function and applications in virus-host interaction. Virology 2008, 382:115-123. 10.1016/j.virol.2008.08.047.
31. Tu YB, Wang YQ, Wang G, Wu JN, Liu YG, Wang SJ, Jiang CG, Cai XH. High-level expression and immunogenicity of a porcine circovirus type 2 capsid protein through codon optimization in Pichia pastoris. Appl Microbiol Biotechnol 2013, 97:2867-2875. 10.1007/s00253-012-4540-z.
32. Tan M, Fang PA, Xia M, Chachiyo T, Jiang W, Jiang X. Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles. Virology 2011, 410:345-352. 10.1016/j.virol.2010.11.017.
33. Tan M, Huang PW, Xia M, Fang PA, Zhong WM, McNeal M, Wei C, Jiang W, Jiang X. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 2011, 85:753-764. 10.1128/JVI.01835-10.
34. Huhti L, Tamminen K, Vesikari T, Blazevic V. Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography. Arch Virol 2013, 158:933-942. 10.1007/s00705-012-1565-7.
35. Tan M, Jiang X. The P domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J Virol 2005, 79:14017-14030. 10.1128/JVI.79.22.14017-14030.2005.
36. Uusi-Kerttula H, Tamminen K, Malm M, Vesikari T, Blazevic V. Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assays. Microbes Infect 2014, 16:472-480. 10.1016/j.micinf.2014.02.010.
37. McCarter JD, Withers SG. Unequivocal identification of Asp-214 as the catalytic nucleophile of Saccharomyces cerevisiae alpha-glucosidase using 5-fluoro glycosyl fluorides. J Biol Chem 1996, 271:6889-6894. 10.1074/jbc.271.12.6889.
38. Huang PW, Farkas T, Marionneau S, Zhong WM, Ruvoen-Clouet N, Morrow AL, Altaye M, Pickering LK, Newburg DS, LePendu J, Jiang X. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: Identification of 4 distinct strain-specific patterns. J Infect Dis 2003, 188:19-31. 10.1086/375742.
39. Damasceno LM, Lee F, Ritter G, Old L, Batt C. High-Level Expression of a Phage Display-Derived scFv in Pichia Pastoris. Antibody Phage Display: Methods and Protocols, Second Edition. Volume 562 2009, 225-236. Humana Press Inc, Totowa, Aitken R, [Methods in Molecular Biology], 10.1007/978-1-60327-302-2_18.
40. Tan M, Jiang X. Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol 2011, 19:382-388. 10.1016/j.tim.2011.05.007.
41. Huhti L, Blazevic V, Nurminen K, Koho T, Hytonen VP, Vesikari T. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol 2010, 155:1855-1858. 10.1007/s00705-010-0768-z.
42. Lowe AJ, Bardliving CL, Huang CJ, Teixeira LM, Damasceno LM, Anderson KA, Ritter G, Old LJ, Batt CA. Expression and purification of cGMP grade NY-ESO-1 for clinical trials. Biotechnol Prog 2011, 27:435-441. 10.1002/btpr.552.
43. Shi L, Sanyal G, Ni A, Luo Z, Doshna S, Wang B, Graham TL, Wang N, Volkin DB. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci 2005, 94:1538-1551. 10.1002/jps.20377.
44. Lin-Cereghino GP, Stark CM, Kim D, Chang J, Shaheen N, Poerwanto H, Agari K, Moua P, Low LK, Tran N, Huang AD, Nattestad M, Oshiro KT, Chang JW, Chavan A, Tsai JW, Lin-Cereghino J. The effect of α-mating factor secretion signal mutations on recombinant protein expression in Pichia pastoris. Gene 2013, 519:311-317. 10.1016/j.gene.2013.01.062.
45. Carreras-Sangrà N, Tomé-Amat J, García-Ortega L, Batt CA, Oñaderra M, Martínez-del-Pozo T, Gavilanes JG, Lacadena J. Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin. Protein Eng Des Sel 2012, 25:425-435. 10.1093/protein/gzs032.
46. Tome-Amat J, Menendez-Mendez A, Garcia-Ortega L, Batt CA, Onaderra M, Martinez-del-Pozo A, Gavilanes JG, Lacadena J. Production and characterization of scFvA33T1, an immunoRNase targeting colon cancer cells. Febs J 2012, 279:3022-3032. 10.1111/j.1742-4658.2012.08683.x.
47. Damasceno LM, Pla I, Chang HJ, Cohen L, Ritter G, Old LJ, Batt CA. An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris. Protein Expr Purif 2004, 37:18-26. 10.1016/j.pep.2004.03.019.
48. Jewell SN, Waldo RH, Cain CC, Falkinham JO. Rapid detection of lytic antimicrobial activity against yeast and filamentous fungi. J Microbiol Methods 2002, 49:1-9. 10.1016/S0167-7012(01)00360-8.
49. Koho T, Mantyla T, Laurinmaki P, Huhti L, Butcher SJ, Vesikari T, Kulomaa MS, Hytonen VP. Purification of norovirus-like particles (VLPs) by ion exchange chromatography. J Virol Methods 2012, 181:6-11. 10.1016/j.jviromet.2012.01.003.